C4 Therapeutics, Inc. (CCCC)
3.79
0.00 (0.00%)
USD |
NASDAQ |
Sep 03, 12:49
C4 Therapeutics Research and Development Expense (Annual) : 104.24M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 104.24M |
| December 31, 2024 | 110.64M |
| December 31, 2023 | 117.71M |
| December 31, 2022 | 117.84M |
| Date | Value |
|---|---|
| December 31, 2021 | 94.66M |
| December 31, 2020 | 76.82M |
| December 31, 2019 | 46.56M |
| December 31, 2018 | 27.39M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Beam Therapeutics, Inc. | 409.62M |
| Rallybio Corp. | 16.30M |
| Q32 Bio, Inc. | 19.16M |
| Arrowhead Pharmaceuticals, Inc. | 585.26M |
| Oncolytics Biotech, Inc. | 13.31M |